LON:FAB - Fusion Antibodies Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started GBX 125 0.00 (0.00 %) (As of 07/16/2018 04:57 AM ET)Previous CloseGBX 125Today's RangeGBX 125 - GBX 12552-Week RangeGBX 85 - GBX 224.90VolumeN/AAverage Volume5,604 shsMarket Capitalization£23.53 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileInsider TradesHeadlinesChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fusion Antibodies plc, a biotech contract research organization, provides pre-clinical antibody drug discovery and development services. The company offers a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of monoclonal antibodies. In addition, the company provides antibody sequencing; custom expression and purification of recombinant proteins; transient protein expression; and stable cell line development services, as well as supplies materials for clinical trials. It serves pharma, biotech, and research institute clients worldwide. The company has a partnership with Protein Alternatives to develop humanized antibodies for therapeutic development; and Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom. Receive FAB News and Ratings via Email Sign-up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolLON:FAB CUSIPN/A Webfusionantibodies.com Phone+44-28-90432800 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-11.77% Return on Equity-18.87% Return on Assets-13.97% Miscellaneous EmployeesN/A Outstanding Shares22,090,000Market Cap£23.53 Fusion Antibodies (LON:FAB) Frequently Asked Questions What is Fusion Antibodies' stock symbol? Fusion Antibodies trades on the London Stock Exchange (LON) under the ticker symbol "FAB." What is the consensus analysts' recommendation for Fusion Antibodies? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Antibodies in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Fusion Antibodies' key competitors? Some companies that are related to Fusion Antibodies include Motif Bio (MTFB), Innovation Pharmaceuticals (IPIX), 4d Pharma (DDDD), Helix Biopharma (HBP), Ergomed (ERGO), Cardiome Pharma (COM), GB Sciences (GBLX), OncoCyte (OCX), InMed Pharmaceuticals (IMLFF), Navidea Biopharmaceuticals (NAVB), Botanix Pharmaceuticals (BOT), IntelGenx Technologies (IGX), BELLUS Health (BLU), Medicenna Therapeutics (MDNA) and Destiny Pharma (DEST). Who are Fusion Antibodies' key executives? Fusion Antibodies' management team includes the folowing people: Dr. Paul Gerard Kerr, CEO & DirectorProf. Jim Johnston, FounderMr. James Fair, CFO, Company Sec. & DirectorDr. Richard John Buick, CTO & DirectorDr. Alan McBride Ph.D., Scientific Research Mang. Has Fusion Antibodies been receiving favorable news coverage? Media coverage about FAB stock has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fusion Antibodies earned a coverage optimism score of 0.10 on Accern's scale. They also gave media headlines about the company an impact score of 43.26 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. How do I buy shares of Fusion Antibodies? Shares of FAB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Fusion Antibodies' stock price today? One share of FAB stock can currently be purchased for approximately GBX 125. How big of a company is Fusion Antibodies? Fusion Antibodies has a market capitalization of £23.53 million. How can I contact Fusion Antibodies? Fusion Antibodies' mailing address is Springbank Industrial Estate 1 Springbank Road, BELFAST, NIR BT17 0QL, United Kingdom. The company can be reached via phone at +44-28-90432800. MarketBeat Community Rating for Fusion Antibodies (LON FAB)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 17 (Vote Outperform)Underperform Votes: 16 (Vote Underperform)Total Votes: 33MarketBeat's community ratings are surveys of what our community members think about Fusion Antibodies and other stocks. Vote "Outperform" if you believe FAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FAB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?